BioSpace News Archive

Rising Biosciences, Inc. (OTC PINK:RBII) CEO Arthur Hall reported that the company is expecting to achieve and surpass a milestone sales benchmark in the fiscal year 2020.

Congratulations to Mike Melo, LifeLabs’ Chief Information Security Officer (CISO), for being awarded ‘CISO of the Year’ at the 2020 CISO Forum Canada. The award, presented by the world’s leading Cybersecurity and e-Business certification awarding body (and the creator of the world famous Certified Ethical Hacker certification) EC-Council and siberX, recognizes one individual who has truly navigated through the new normal with an innovative and strong

Worldwide Clinical Trials employs more than 1,900 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class

Using wastewater-based epidemiology techniques, SARS-CoV-2 is detectable up to a week before the traditional onset of COVID-19 symptoms within a population, giving communities more time to react.

HUMANETICS GROUP, the global safety, sensor and precision engineering business, announced that Amit Singhi has joined the Humanetics Group as Chief Financial Officer reporting to Chris O’Connor, President and CEO.

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on November 30, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 51,500 shares of its common stock to three new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.

atbtherapeutics, a pioneering biopharmaceutical company building an oncology pipeline using its antibody–toxin-bioengineered “atbody”, announces that it has entered a long-term manufacturing agreement with iBio CDMO, a global leader in plant-based biologics manufacturing located in the US.

Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved a Phase IIa clinical study of the company’s novel MDM2-p53 inhibitor APG-115,

ImpediMed Limited, a global medical technology company using bioimpedance spectroscopy to generate powerful data to improve patient health, announced the publication of a new study demonstrating that the company’s Lymphedema Prevention Program reduces the incidence of chronic breast cancer-related lymphedema in breast cancer patients and survivors.

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, announced the closing of its Series F Preferred Stock financing led by D1 Capital Partners and new equity partner Janus Henderson Investors.